Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is There A REMS In Uloric’s Future? US FDA Panelists Say Yes, Agency Says Not Likely

Executive Summary

Continued availability of Takeda’s febuxostat should be restricted to second-line use in gout patients who cannot tolerate or fail allopurinol, advisory committee majority says, opposing market withdrawal; but panelists’ suggestion that a Risk Evaluation and Mitigation Strategy be put in place to ensure patients and prescribers discuss cardiovascular risks receives pushback from agency.

Advertisement

Related Content

Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint
Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases
Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options
Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating
Waiting For Next Regulatory Shoe To Drop For Takeda's Gout Drug Uloric
Vascepa Negative Panel Vote Clouds Future For Other Cholesterol Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel